Effective AAV-mediated gene therapy in a mouse model of ethylmalonic encephalopathy

Ivano Di Meo, Alberto Auricchio, Costanza Lamperti, Alberto Burlina, Carlo Viscomi, Massimo Zeviani

Research output: Contribution to journalArticle

Abstract

Ethylmalonic encephalopathy (EE) is an invariably fatal disease, characterized by the accumulation of hydrogen sulfide (H2S), a highly toxic compound. ETHE1, encoding sulfur dioxygenase (SDO), which takes part in the mitochondrial pathway that converts sulfide into harmless sulfate, is mutated in EE. The main source of H2S is the anaerobic bacterial flora of the colon, although in trace amount it is also produced by tissues, where it acts as a 'gasotransmitter'. Here, we show that AAV2/8-mediated, ETHE1-gene transfer to the liver of a genetically, metabolically and clinically faithful EE mouse model resulted in full restoration of SDO activity, correction of plasma thiosulfate, a biomarker reflecting the accumulation of H2S, and spectacular clinical improvement. Most of treated animals were alive and well >6-8 months after birth, whereas untreated individuals live 26±7 days. Our results provide proof of concept on the efficacy and safety of AAV2/8-mediated livergene therapy for EE, and alike conditions caused by the accumulation of harmful compounds in body fluids and tissues, which can directly be transferred to the clinic.

Original languageEnglish
Pages (from-to)1008-1014
Number of pages7
JournalEMBO Molecular Medicine
Volume4
Issue number9
DOIs
Publication statusPublished - Sep 2012

Fingerprint

Genetic Therapy
Gasotransmitters
Thiosulfates
Hydrogen Sulfide
Poisons
Body Fluids
Sulfides
Sulfates
Colon
Biomarkers
Parturition
Safety
Ethylmalonic encephalopathy
Liver
Genes
sulfur dioxygenase
Therapeutics

Keywords

  • Adeno-associated virus
  • Ethylmalonic encephalopathy
  • Gene therapy
  • Hydrogen sulfide
  • Mitochondrial disease

ASJC Scopus subject areas

  • Molecular Medicine

Cite this

Effective AAV-mediated gene therapy in a mouse model of ethylmalonic encephalopathy. / Di Meo, Ivano; Auricchio, Alberto; Lamperti, Costanza; Burlina, Alberto; Viscomi, Carlo; Zeviani, Massimo.

In: EMBO Molecular Medicine, Vol. 4, No. 9, 09.2012, p. 1008-1014.

Research output: Contribution to journalArticle

Di Meo, Ivano ; Auricchio, Alberto ; Lamperti, Costanza ; Burlina, Alberto ; Viscomi, Carlo ; Zeviani, Massimo. / Effective AAV-mediated gene therapy in a mouse model of ethylmalonic encephalopathy. In: EMBO Molecular Medicine. 2012 ; Vol. 4, No. 9. pp. 1008-1014.
@article{990df9bf57114baea0ba875519fcf307,
title = "Effective AAV-mediated gene therapy in a mouse model of ethylmalonic encephalopathy",
abstract = "Ethylmalonic encephalopathy (EE) is an invariably fatal disease, characterized by the accumulation of hydrogen sulfide (H2S), a highly toxic compound. ETHE1, encoding sulfur dioxygenase (SDO), which takes part in the mitochondrial pathway that converts sulfide into harmless sulfate, is mutated in EE. The main source of H2S is the anaerobic bacterial flora of the colon, although in trace amount it is also produced by tissues, where it acts as a 'gasotransmitter'. Here, we show that AAV2/8-mediated, ETHE1-gene transfer to the liver of a genetically, metabolically and clinically faithful EE mouse model resulted in full restoration of SDO activity, correction of plasma thiosulfate, a biomarker reflecting the accumulation of H2S, and spectacular clinical improvement. Most of treated animals were alive and well >6-8 months after birth, whereas untreated individuals live 26±7 days. Our results provide proof of concept on the efficacy and safety of AAV2/8-mediated livergene therapy for EE, and alike conditions caused by the accumulation of harmful compounds in body fluids and tissues, which can directly be transferred to the clinic.",
keywords = "Adeno-associated virus, Ethylmalonic encephalopathy, Gene therapy, Hydrogen sulfide, Mitochondrial disease",
author = "{Di Meo}, Ivano and Alberto Auricchio and Costanza Lamperti and Alberto Burlina and Carlo Viscomi and Massimo Zeviani",
year = "2012",
month = "9",
doi = "10.1002/emmm.201201433",
language = "English",
volume = "4",
pages = "1008--1014",
journal = "EMBO Molecular Medicine",
issn = "1757-4676",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Effective AAV-mediated gene therapy in a mouse model of ethylmalonic encephalopathy

AU - Di Meo, Ivano

AU - Auricchio, Alberto

AU - Lamperti, Costanza

AU - Burlina, Alberto

AU - Viscomi, Carlo

AU - Zeviani, Massimo

PY - 2012/9

Y1 - 2012/9

N2 - Ethylmalonic encephalopathy (EE) is an invariably fatal disease, characterized by the accumulation of hydrogen sulfide (H2S), a highly toxic compound. ETHE1, encoding sulfur dioxygenase (SDO), which takes part in the mitochondrial pathway that converts sulfide into harmless sulfate, is mutated in EE. The main source of H2S is the anaerobic bacterial flora of the colon, although in trace amount it is also produced by tissues, where it acts as a 'gasotransmitter'. Here, we show that AAV2/8-mediated, ETHE1-gene transfer to the liver of a genetically, metabolically and clinically faithful EE mouse model resulted in full restoration of SDO activity, correction of plasma thiosulfate, a biomarker reflecting the accumulation of H2S, and spectacular clinical improvement. Most of treated animals were alive and well >6-8 months after birth, whereas untreated individuals live 26±7 days. Our results provide proof of concept on the efficacy and safety of AAV2/8-mediated livergene therapy for EE, and alike conditions caused by the accumulation of harmful compounds in body fluids and tissues, which can directly be transferred to the clinic.

AB - Ethylmalonic encephalopathy (EE) is an invariably fatal disease, characterized by the accumulation of hydrogen sulfide (H2S), a highly toxic compound. ETHE1, encoding sulfur dioxygenase (SDO), which takes part in the mitochondrial pathway that converts sulfide into harmless sulfate, is mutated in EE. The main source of H2S is the anaerobic bacterial flora of the colon, although in trace amount it is also produced by tissues, where it acts as a 'gasotransmitter'. Here, we show that AAV2/8-mediated, ETHE1-gene transfer to the liver of a genetically, metabolically and clinically faithful EE mouse model resulted in full restoration of SDO activity, correction of plasma thiosulfate, a biomarker reflecting the accumulation of H2S, and spectacular clinical improvement. Most of treated animals were alive and well >6-8 months after birth, whereas untreated individuals live 26±7 days. Our results provide proof of concept on the efficacy and safety of AAV2/8-mediated livergene therapy for EE, and alike conditions caused by the accumulation of harmful compounds in body fluids and tissues, which can directly be transferred to the clinic.

KW - Adeno-associated virus

KW - Ethylmalonic encephalopathy

KW - Gene therapy

KW - Hydrogen sulfide

KW - Mitochondrial disease

UR - http://www.scopus.com/inward/record.url?scp=84865725896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865725896&partnerID=8YFLogxK

U2 - 10.1002/emmm.201201433

DO - 10.1002/emmm.201201433

M3 - Article

C2 - 22903887

AN - SCOPUS:84865725896

VL - 4

SP - 1008

EP - 1014

JO - EMBO Molecular Medicine

JF - EMBO Molecular Medicine

SN - 1757-4676

IS - 9

ER -